Why It Is Moving

Why It Is Moving Recent News

GE HealthCare's First Annual Financial Performance As Public Company Shows Strength, FY24 Outlook Exceed Investor Expectations
GE Healthcare's Q4 2023 performance with sales of $5.21 billion, a 5% YoY increase. GEHC shares surge 10.8% to $81.30. Get the latest on fiscal year 2024 forecasts.
|
Credit Suisse Consolidation Weighs On UBS, Stock Tanks On Q4 Performance
UBS reports Q4 2023 sales of $10.9 billion, up 35% YoY, exceeding consensus. CEO Sergio Ermotti shares insights on the year's milestones.
|
Investors Cheer Eli Lilly Earnings, Q4 Performance Surpasses Expectations Thanks To Strong Zepbound Launch, Surging Weight Loss Drug Sales
Eli Lilly beats Q4 2023 revenue expectations at $9.35 billion, driven by higher realized prices and strong sales of Mounjaro, Verzenio, and Jardiance.
|
Elanco Animal Health To Offload Aqua Business For $1.3B, Plans To Lower Debt Burden
"Merck Animal Health expands aqua portfolio with the $1.3 billion acquisition of Elanco's aqua business. Expected completion by mid-2024."
|
Why Is Life Science Tools Firm NanoString Stock Trading Lower Today?
NanoString Technologies' Chapter 11 restructuring and strategic alternatives amid patent litigation challenges and a $31 million damages verdict.
|
Why Is DNA Synthesis Company Twist Bioscience Stock Trading Higher Today?
Twist Bioscience reported Q1 2024 earnings, beating revenue guidance and increasing FY24 guidance. Shares are up 7.16%.
|
Why Is Health Insurance Plan Provider Cigna Stock Trading Higher Today?
Cigna's robust Q4 2023 performance with $51.15 billion in sales, up 12% Y/Y. Dive into the growth of Cigna Healthcare, Evernorth Health Services.
|
Why Is Apple Stock Sliding Nearly 3% Premarket Amid Tech Surge?
Apple succeeded in snapping a four-session revenue decline streak but its underperformance in China and soft guidance has hurt the stock.
|
Why Is European Pharma Giant Novartis Stock Trading Lower Today?
Novartis Q4 2023 sales reach $11.42 billion, up 8%. Strong growth in key drugs, Entresto, Kisqali, Kesimpta, Cosentyx, and Pluvicto. Core operating income at $3.8 billion.
|
Pharma Giant Gilead Raises Stake In Cancer-Focused Arcus Biosciences, Stock Soars
Arcus Biosciences sees a 17.1% surge as Gilead Sciences amends collaboration, investing $320M at $21.00/share. Accelerate joint programs in cancer therapy.
|
Roche Walks Away From HOOKIPA Pharma-Partnered KRAS-Focused Cancer Deal
HOOKIPA Pharma's strategic focus on HB-200 program for HPV16+ HNSCC, infectious disease cure collaboration with Gilead, and recent developments.
|
Why Is Precision Oncology-Focused Corbus Pharmaceuticals Stock Trading Higher Today?
Corbus Pharma's CRB-701 exhibits 43% ORR and 71% disease control in urothelial cancer trial.
|
Alaska Air Warns Boeing Fleet Grounding Incident To Hit 2024 Earnings By $150M
"Alaska Air Group Inc (NYSE: ALK) reports Q4 revenue of $2.55B, up 3% YoY. Boeing 737 MAX updates, and 2024 earnings guidance.
|
Why Is Cancer Focused LAVA Therapeutics Nano Cap Stock Trading Higher Today?
LAVA Therapeutics collaborates with Merck on a clinical trial for anti-PD-1 therapy Keytruda in metastatic castration-resistant prostate cancer.
|
Why Is American Airlines Stock Flying Higher Today?
AAL reports 4Q23 earnings of $0.29 per share, above estimates. Revenue also beats expectations. Despite 737 Max concerns, AAL plans for growth.
|
Why Is Cancer Therapy Focused Evaxion Biotech Stock Trading Higher Today?
Evaxion Biotech revolutionizes cancer vaccine development, targeting AI-identified ERVs. Preclinical activities underway; Proof-of-Concept data expected by 2H 2024.
|
Abbott Laboratories Surpasses Q4 Sales Expectations, Despite Dip In COVID-19 Testing Demand
Abbott Laboratories exceeds expectations with Q4 sales of $10.24B, showcasing resilience despite softer demand for COVID-19 testing. CEO anticipates continued growth in 2024.
|
Why Is Cancer Focused Kura Oncology Stock Is Trading Higher Today?
Latest surge in Kura Oncology shares with a $150 million private placement announcement. Cash runway extended into 2027.
|

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2025 Benzinga | All Rights Reserved